High-dose flu vaccine may better protect older adults, regardless of diabetes status, against cardiovascular and influenza-related outcomes than the standard dose, a DANFLU-2 trial analysis suggests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback